Supporting Data Release Notes – 4.62

May 23, 2025

# Overview

Release 4.62 includes significant contraindication improvements. Existing vaccine specific contraindications for discontinued (or never U.S. active vaccines) have been removed. New vaccine specific contraindications were added for combination vaccines to support cross-antigen contraindications. For example, if a patient has a specific contraindication to HepB vaccination the patient should be contraindicated to Twinrix in both the HepA and HepB supporting data.

This release notes document provides a high-level list of changes. More specific details can be found inside supporting data spreadsheets in the Change History tab. A color-coded version of the Supporting Data changes from 4.61 to 4.62 is available upon request. Please email [iisinfo@cdc.gov](mailto:iisinfo@cdc.gov).

# Structural Changes

* n/a

# Schedule Supporting Data Changes

Table 1: Schedule Supporting Data Changes

|  |  |
| --- | --- |
| **Supporting Data** | **Change** |
| Coded Observations | * Added new code 275 - persons at risk during a measles outbreak * Added new code 276 – person is aged 60 years or older (for Chikungunya safety pause) |

# Antigen Series Supporting Data Changes

Table 2: Antigen Series Specific Supporting Data Changes

|  |  |
| --- | --- |
| **Supporting Data** | **Change** |
| Chikungunya | * FDA and CDC have issued a pause on the use of Ixchiq in persons 60 years or older. |
| COVID-19 | * Removed vaccine-specific contraindications where the vaccines are no longer active U.S. vaccine products * Adjusted skip condition context on last dose of age-based series * Added a maximum age on dose 1 of the Novavax early start series * Created empty (e.g., all n/a) Age entries into all age and risk-based series focused on persons starting vaccination under 5 years of age |
| Diphtheria | * Added new antigen contraindications * Removed vaccine-specific contraindications where the vaccines are no longer active U.S. vaccine products * Added new vaccine-specific contraindications for combination vaccines. Combination vaccines are contraindicated when any single component is contraindicated |
| HepA | * Added new vaccine-specific contraindications for combination vaccines. Combination vaccines are contraindicated when any single component is contraindicated * Added HIV Infection with known severity (codes 154 and 155) to existing series with HIV Infection without documented severity (code 186). Any evidence of HIV infection would indicate vaccination. |
| HepB | * Removed vaccine-specific contraindications where the vaccines are no longer active U.S. vaccine products * Added new vaccine-specific contraindications for combination vaccines. Combination vaccines are contraindicated when any single component is contraindicated * Added HIV Infection with known severity (codes 154 and 155) to existing series with HIV Infection without documented severity (code 186). Any evidence of HIV infection would indicate vaccination. |
| Hib | * Removed 2 contraindications (Chemotherapy and radiation therapy) as these were also an indication causing confusion. The intent of the contraindication was moved to be administrative guidance of the indication * Removed vaccine-specific contraindications where the vaccines are no longer active U.S. vaccine products * Added new vaccine-specific contraindications for combination vaccines. Combination vaccines are contraindicated when any single component is contraindicated * Added sickle cell disease (code 259) as a new indication to all Immunocompromised series to support patients who have sickle cell disease, but no documentation of asplenia on their record * Added HIV Infection with known severity (codes 154 and 155) to existing series with HIV Infection without documented severity (code 186). Any evidence of HIV infection would indicate vaccination. |
| HPV | * Added HIV Infection with known severity (codes 154 and 155) to existing series with HIV Infection without documented severity (code 186). Any evidence of HIV infection would indicate vaccination. |
| Influenza | * Removed vaccine-specific contraindications where the vaccines are no longer active U.S. vaccine products * Added HIV infection without documented severity (code 186) as a vaccine contraindication to LAIV. Codes 154 and 155 (HIV with known severity) were both already included. |
| Measles | * Added new antigen contraindications * Added new vaccine-specific contraindications for combination vaccines. Combination vaccines are contraindicated when any single component is contraindicated * Added new indication to existing risk 1-dose series |
| Meningococcal ACWY | * Added support in Aged-based series for catch-up vaccination support for those 19 through 21 years of age. * Added sickle cell disease (code 259) as a new indication to all Immunocompromised series to support patients who have sickle cell disease, but no documentation of asplenia on their record * Added HIV Infection with known severity (codes 154 and 155) to existing series with HIV Infection without documented severity (code 186). Any evidence of HIV infection would indicate vaccination. |
| Meningococcal B | * Added sickle cell disease (code 259) as a new indication to all Immunocompromised series to support patients who have sickle cell disease, but no documentation of asplenia on their record |
| Mumps | * Added new antigen contraindications * Added new vaccine-specific contraindications for combination vaccines. Combination vaccines are contraindicated when any single component is contraindicated |
| Pertussis | * Added new antigen contraindications * Removed vaccine-specific contraindications where the vaccines are no longer active U.S. vaccine products * Added new vaccine-specific contraindications for combination vaccines. Combination vaccines are contraindicated when any single component is contraindicated |
| Pneumococcal | * Harmonized the absolute minimum age and minimum age on dose 2 in the Risk 19+ CMC and CSF CI series to improve forecasting. Doses 2 and 3 were updated in the 19+ IC series with the same harmonization * Technical correction to change the Default Series value to “No” in the recently created “50+ 2-dose PCV13” series * Added sickle cell disease (code 259) as a new indication to all Immunocompromised series to support patients who have sickle cell disease, but no documentation of asplenia on their record * Added HIV Infection with known severity (codes 154 and 155) to existing series with HIV Infection without documented severity (code 186). Any evidence of HIV infection would indicate vaccination. * Added PCV20 as a preferable vaccine to dose 2 of Risk 6-18 years series (PCV-PPSV and PCV-PPSV-PPSV). |
| Polio | * Added new vaccine-specific contraindications for combination vaccines. Combination vaccines are contraindicated when any single component is contraindicated |
| RSV | * Adjusted absolute minimum age to provide a lower bound for the single lifetime dose and avoid false outcomes when infants may have inadvertently received the vaccine rather than nirsevimab |
| Rubella | * Added new antigen contraindications * Added new vaccine-specific contraindications for combination vaccines. Combination vaccines are contraindicated when any single component is contraindicated |
| Tetanus | * Added new antigen contraindications * Removed vaccine-specific contraindications where the vaccines are no longer active U.S. vaccine products * Added new vaccine-specific contraindications for combination vaccines. Combination vaccines are contraindicated when any single component is contraindicated |
| Varicella | * Added new vaccine-specific contraindications for combination vaccines. Combination vaccines are contraindicated when any single component is contraindicated |
| Yellow Fever | * Removed vaccine-specific contraindications where the vaccines are no longer active U.S. vaccine products |
| Zoster | * Added HIV Infection with known severity (codes 154 and 155) to existing series with HIV Infection without documented severity (code 186). Any evidence of HIV infection would indicate vaccination. |